

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 323 765 813 US, in an envelope addressed to: **MS Patent Application**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 16, 2004

Signature: 

(Juan Quintero)

Docket No.: 29915/00281E
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: *Yan et al.*

Application No.: Not Yet Assigned

Art Unit: Not Yet Assigned

Filed: March 16, 2004 (herewith)

Examiner: Not Yet Assigned

For: SUBSTRATES AND ASSAYS FOR BETA-
SECRETASE ACTIVITY

**This application is filed as a Divisional
application of U.S. Patent Application No.
09/908,943, which was filed July 19, 2001**

INFORMATION DISCLOSURE STATEMENT

MS Patent Application

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Attached herewith are Form 1449A/PTO forms that were submitted in parent application U.S. Patent Application No. 09/908,943. These copies are hereby submitted by the Applicants for consideration in connection with the above-identified patent application in compliance with 37 C.F.R. §1.97 and the duty of disclosure under 37 C.F.R. §1.56.

In accordance with 37 C.F.R. §1.98(d)(1), copies of the references cited on the Form 1449A/PTO are not attached hereto because those references have previously been provided in U.S. Patent Application No. 09/908,943, which was filed July 19, 2001. The present application is a divisional of the aforementioned application, which is relied on for an earlier effective filing date under 35 U.S.C. §120. However, should the Examiner require copies of one or more of the references cited in the prior application, Applicants will furnish the documents upon request.

Application No.: Not Yet Assigned
Information Disclosure Statement to
Accompany New Divisional Application
of U.S. Serial No. 09/908,943

Docket No.: 29915/00281E

This information disclosure statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. §102 or 35 U.S.C. §103.

This statement and the Form 1449A/PTO are being submitted with the application filing papers and as such are submitted before receipt of a first Office Action in the above-identified patent application. Accordingly, it is submitted that no fee is due in this matter under 37 C.F.R. §1.97(b). However, if it is determined that any appropriate fee is due, please charge Deposit Account Number 13-2855. A duplicate of this paper is enclosed.

Dated: March 16, 2004

Respectfully submitted,

By 
Nabeela R. McMillian, Ph.D.

Registration No.: 43,363

MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorney for Applicant

PATENT
29915/00281A.US1

IN THE UNITED STATES
PATENT AND TRADEMARK OFFICE

Applicants: Yan *et al.*

Serial No.: 09/908,943

Filed: July 19, 2001

**For: SUBSTRATES AND ASSAYS FOR
BETA-SECRETASE ACTIVITY**

Group Art Unit: 1645

Examiner: To be assigned

) I hereby certify that this paper is
) being deposited with the United
) States Postal Service as first class
) mail, postage prepaid, in an envelope
) addressed to: Commissioner for
) Patents, Washington, DC 20231, on
) this date:

November 19, 2001

) Nabeela R. McMillian
) Registration No. 43,363
) Agent for Applicants

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

The patents and/or publications listed on the enclosed Form PTO-1449 are submitted pursuant to 37 CFR §§ 1.56, 1.97, and 1.98. Copies of the patents or publications are enclosed as necessary.


This Information Disclosure Statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. §102 or §103.

This Information Disclosure Statement is submitted before receipt of a first Office action on the merits, and consequently should be considered by the Patent Office without payment of a fee. See 37 C.F.R. §1.97(b). However, please charge any necessary fees due in connection with this Information Disclosure Statement to Deposit Account No. 13-2855. A copy of this paper is enclosed herewith.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

By:



Nabeela R. McMillian
Reg. No: 43,363
Agent for Applicants

November 19, 2001

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAny. Docket No.
29915/00281ASerial No.
09/908,843

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
Yan *et al.*Filing Date
July 19, 2001Group
1645

U.S. PATENT DOCUMENTS

*Examiner Initials	Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Document Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No
	B1	WO 00/17369	30/03/2000	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C1	Haass <i>et al.</i> , "Processing of β -Amyloid Precursor Protein in Microglia and Astrocytes Favors an Internal Localization over Constitutive Secretion", <i>The Journal of Neuroscience</i> , 11(12):3783-3793
	C2	Kang <i>et al.</i> , "The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor", <i>Nature</i> , 325:733-736 (1987)
	C3	Kitaguchi <i>et al.</i> , "Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity", <i>Nature</i> , 331:530-532 (1988)
	C4	Lin <i>et al.</i> , "Inhibition of Cathepsin D by Synthetic Oligonucleotides", <i>The Journal of Biological Chemistry</i> , 254:11875-11883 (1979)
	C5	Lin <i>et al.</i> , "Human aspartic protease memapsin 2 cleaves the β -secretase site of β -amyloid precursor protein", <i>PNAS</i> , 97:1456-1460 (2000)
	C6	Ponte <i>et al.</i> , "A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors", <i>Nature</i> , 331:525-527 (1988)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
29915/00281ASerial No.
09/908,843**INFORMATION DISCLOSURE STATEMENT**Applicant
Yan *et al.*Filing Date
July 19, 2001Group
1645

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C7	Schechter <i>et al.</i> , "On the Active Site of Proteases, III. Mapping the Active Site of Papain; Specific Peptide Inhibitors of Papain", <i>Biochemical and Biophysical Research Communications</i> , 32:898-902 (1968)
C8	Schechter <i>et al.</i> , "On the Size of the Active Site in Proteases, I. Papain", <i>Biochemical and Biophysical Research Communications</i> , 27:157-162 (1967)
C9	Sinha <i>et al.</i> , "Cellular mechanisms of β -amyloid production and secretion", <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 96:11049-11053 (1999)
C10	Tanzi <i>et al.</i> , "Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease", <i>Nature</i> , 331:528-530 (1988)
C11	Vassar <i>et al.</i> , " β -Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE", <i>Science</i> , 286:735-741 (1999)
C12	Yan <i>et al.</i> , "Membrane-anchored aspartyl protease with Alzheimer's disease β -secretase activity", <i>Nature</i> , 402:533-537 (1999)
C13	Younkin, "Processing of the Alzheimer's Disease β A4 Amyloid Protein Precursor (APP)", <i>Brain Pathology</i> , 1:253-262 (1991)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: May 6, 2003

Signature:


Nabeela R. McMillian

Docket No.: 29915/00281A
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Yan *et al.*

Application No.: 09/908,943

Group Art Unit: 1652

Filed: July 19, 2001

Examiner: Charles L. Patterson, Jr.

For: SUBSTRATES AND ASSAYS FOR
β-SECRETASE ACTIVITY

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO - 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

All patents and publications in the attached Form PTO - 1449 are supplied herewith. It is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for the instant application under any section of 35 U.S.C. §102 or 35 U.S.C. §103.

In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. 1.98 and the Examiner is respectfully requested to consider the listed references.

BEST AVAILABLE COPY

Application No.: 09/908,943

Docket No.: 29915/00281A

In accordance with 37 C.F.R. §1.97(e)(2), individuals designated in § 1.56(c) were not aware of the reference cited herewith more than three months prior to the filing of this Information Disclosure Statement. Therefore, no fees are believed to be necessary, however, the Commissioner is hereby authorized to charge any deficiency in the fees filed or credit any overpayments to our Deposit Account No. 13-2855. A duplicate copy of this paper is enclosed.

Dated: May 6, 2003

Respectfully submitted,

By *Nabeela R. McMillian*
Nabeela R. McMillian

Registration No.: 43,363
MARSHALL, GERSTEIN & BORUN
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorneys for Applicants

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No 29915/00281A	Serial No 09/908,943
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		Applicant Yan <i>et al.</i>	
		Filing Date July 19, 2001	Group 1652

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS							
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
		WO 02/094985	11/28/2002	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.</p>	